Latest News — Page 13

How can Portugal close the gap on medication adherence—and what’s at stake for patients, payers and industry? 💊🔍

Our MAP02 analysis maps the current adherence landscape in Portugal, quantifies clinical and economic consequences, and highlights proven interventions—from pharmacist-led programs to digital adherence tools and policy levers—that improve outcomes and reduce costs.

Read the full article for data-driven recommendations and actionable steps for clinicians, payers and pharma.

#SyenzaNews #healthcare #digitalhealth #MarketAccess #healthcarepolicy

Is Lisbon the next European hub for healthcare innovation? 📍🚀

From a surge in HealthTech startups and AI-driven care pilots to stronger public–private partnerships and EU-backed funding, Lisbon is turning research excellence into scalable healthcare solutions.

Read the full piece for the trends, opportunities, and practical takeaways shaping the region’s health ecosystem.

#SyenzaNews #HealthcareInnovation #HealthTech #innovation #DigitalTransformation

Could FDA approvals for Enhertu reshape early-stage breast cancer care? 🔬

The agency has expanded Enhertu into the neoadjuvant/adjuvant setting, signaling a potential shift in treatment algorithms for patients with certain HER2-expressing tumors and raising important questions about clinical outcomes, access, and payer strategies. This piece outlines the regulatory updates, clinical implications, and what stakeholders should watch next.

Read the full analysis to understand the opportunities and challenges ahead. 👇

#SyenzaNews #oncology #regulatoryaffairs #MarketAccess #innovation

Could tariff relief and onshoring agreements reshape global pharmaceutical security? 🔒🏭

Governments are using targeted agreements and tariff incentives to bring drug manufacturing closer to home—reducing dependence on single-source suppliers, attracting investment, and strengthening supply-chain resilience. This article breaks down the policy tools, industry implications, and strategic trade-offs companies and policymakers need to weigh.

Read the full analysis to see what these shifts mean for manufacturers, payers, and regulatory strategy.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Could updating VTE risk scores over time help prevent clots in cancer patients? 🔍🩺

Dynamic risk stratification uses time-updated clinical data, biomarkers, and treatment factors to refine venous thromboembolism risk throughout a patient’s cancer journey, enabling more personalized thromboprophylaxis decisions and better balance of bleeding vs. benefit. The article outlines emerging models, digital tools for implementation, and key evidence gaps to address before routine practice change.

Read the full piece to see how dynamic approaches could reshape VTE prevention in oncology.

#SyenzaNews #oncology #precisionmedicine #datascience #innovation

Is digital medicine closing gaps or widening them? 🌐📱

This piece lays out core recommendations to make digital medicine equitable—covering infrastructure, affordability, digital literacy, inclusive design, data governance, interoperability, and reimbursement strategies that policymakers and providers can adopt.

Read the full article for practical steps to ensure digital health works for everyone.

#SyenzaNews #digitalhealth #HealthcareInnovation #DigitalTransformation #healthcarepolicy

Could intranasal delivery be the next leap for fast-acting biologics and CNS therapies? 🚀🌬️

Hovione and IDC have partnered to commercialize an intranasal drug-delivery platform that pairs device innovation with formulation and GMP manufacturing expertise, offering rapid systemic absorption, non‑invasive dosing, and scalable production for peptides, vaccines and CNS-targeted drugs. This approach could shorten time-to-effect, improve patient adherence, and unlock new market opportunities for therapies that struggle with oral or injectable routes.

Read the full article to see how the platform works, regulatory considerations, and which therapeutic areas stand to benefit.

#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Is Portugal’s cannabis market hitting the brakes? 📉🇵🇹

Recent cuts in licensing have visibly contracted the sector — reducing new entrants, cooling investment, and creating supply and patient-access pressures while forcing companies to reassess growth strategies. The article explains the regulatory shifts, market impacts, and what policymakers and businesses can do next.

Read the full analysis to understand the implications and next steps for stakeholders.

#SyenzaNews #regulatoryaffairs #pharmaceuticals #MarketAccess #governance

Can local vaccine manufacturing finally deliver supply security for Africa? 🌍🏭

This article breaks down the practical opportunities and hurdles — from technology transfer and workforce development to financing, regulatory alignment, and regional partnerships — that will determine whether African countries can reduce import dependence and respond faster to future outbreaks. It highlights actionable strategies and policy priorities to scale sustainable, region-wide production.

Read the full piece to explore country examples, investment pathways, and next steps for policymakers and industry.

#SyenzaNews #pharmaceuticals #globalhealth #innovation #healthcarepolicy

Could NICE’s approval of durvalumab reshape gastric cancer care in the UK?

NICE has recommended durvalumab for gastric cancer after an appraisal that weighed clinical benefit and cost-effectiveness, opening the door to broader NHS access and changes to treatment pathways. The article explains the decision drivers, likely timelines for patient access, and implications for clinicians and industry.

Read the full piece to get the details and what to expect next. 🔍

#SyenzaNews #oncology #regulatoryaffairs #MarketAccess #healthcarepolicy

How do bladder cancer treatments affect patients’ quality of life?

This article unpacks the real-world consequences of choices from bladder‑sparing therapies to radical cystectomy and urinary diversion—covering impacts on urinary function, sexual health, body image and psychosocial wellbeing. It also highlights the value of patient‑reported outcomes, multidisciplinary care, and emerging approaches that aim to preserve function and dignity. 🔍🩺

Read the full piece to weigh trade‑offs and discover patient‑centered strategies that improve everyday life for people with bladder cancer.

#SyenzaNews #oncology #HealthcareInnovation #innovation #healthcarepolicy

Can pharmacy-led vaccination programs scale globally without a major training overhaul? 💉🌍

Standardized competency-based curricula, scalable digital learning, and regulatory alignment are critical to prepare pharmacists for safe, widespread vaccine delivery. Coupled with practical supervision, cold-chain investment, and accreditation, these steps can expand access and strengthen pandemic resilience.

Read the full article for practical strategies and policy recommendations to accelerate pharmacy vaccination training worldwide.

#SyenzaNews #pharmaceuticals #globalhealth #healthcarepolicy #innovation

Are you up to date with NICE NG195 on neonatal infection management? 👶🩺

NICE’s new guidance promotes a risk‑based approach to starting and stopping empirical antibiotics, clarifies diagnostic testing and duration decisions, and strengthens antimicrobial stewardship while centering family involvement.

Explore the full article for practical takeaways and what this means for clinicians and neonatal units.

#SyenzaNews #healthcare #HealthcareInnovation #healthcarepolicy #innovation

🌟 How are Merck’s advancements in oncology reshaping cancer treatment?

With significant new data set to be unveiled at ASCO 2026, Merck is enhancing treatment options for cancers like melanoma and lung cancer, demonstrating long-term survival benefits through innovative therapy combinations.

Dive into the insights from their presentations and discover how these breakthroughs could impact patient care.

#SyenzaNews #oncology #drugdevelopment #HealthcareInnovation

Can the EU’s Critical Medicines Act finally end chronic drug shortages? 💊🔗

The new legislation aims to shore up pharma supply chains by diversifying suppliers, boosting on‑shore production and API capacity, and tightening shortage monitoring and joint procurement — shifting regulatory expectations and commercial incentives across the sector. It’s a pivotal moment for manufacturers, regulators and healthcare providers to reassess supply‑chain resilience and investment priorities.

Read the full article for a practical breakdown of the Act’s measures and what steps organisations should take next.

#SyenzaNews #pharmaceuticals #regulatoryaffairs #healthcarepolicy #strategicplanning

🌟 Are you ready to revolutionize mental health care?

Innovations in neuropsychiatry are paving the way for enhanced treatment options for complex conditions like major depressive disorder and schizophrenia. Recent findings from Johnson & Johnson highlight significant advancements that could improve patient outcomes and reduce long-term costs associated with relapse.

Curious to learn how these breakthroughs are shaping the future of mental health treatment? Dive into the full article for a comprehensive analysis!

#SyenzaNews #HealthcareInnovation #MentalHealth #Innovation